Market Overview

UPDATE: Bank of America Raises PT to $70 on Baxter International; Gambro Strategic Fit at Steep Price

Related BAX
Baxter Submits Application for U.S. FDA Approval of BAX111, Investigational Recombinant Treatment for Von Willebrand Disease
Baxter to Divest Vero Cell Vaccines Platform to Nanotherapeutics
Merck Snags Baxter Executive As CFO (Fox Business)

Bank of America reiterated its Buy rating on Baxter International (NYSE: BAX) and increased its price target from $67 to $70.

Bank of America commented, "On Friday the Wall Street Journal and several other media outlets reported that BAX is in talks to acquire privately held Gambro for $4bn (BAX's market cap is $38bn). Gambro is the #2 share player in the hemodialysis technology market where BAX has little presence, and BAX is #1 in the peritoneal dialysis market where Gambro has no presence. In our view, in the hands of BAX, Gambro would be a much tougher HD competitor and a strong strategic fit, with the potential for significant synergies, but a $4bn price tag creates a very high hurdle for positive returns in our view."

Baxter International closed at $67.18 on Friday.

Latest Ratings for BAX

DateFirmActionFromTo
Oct 2014BarclaysMaintainsOverweight
Oct 2014Credit SuisseMaintainsOutperform
Oct 2014Morgan StanleyMaintainsEqual-weight

View More Analyst Ratings for BAX
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (BAX)

Around the Web, We're Loving...

Get Benzinga's Newsletters